Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An intergroup study

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 994-999

  Taylor, Charles W ^a   Green, Stephanie ^a   Dalton, William S ^a   Martino, Silvana ^a   Rector, Dorothy ^a   Ingle, James N ^a   Robert, Nicholas J ^a   Budd, G Thomas ^a   Paradelo, Jorge C ^a   Natale, Ronald B ^a   Bearden, James D ^a   Mailliard, James A ^a   Osborne, C Kent ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; GOSERELIN;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; OVARIECTOMY; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0031887094     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.994     Document Type: Article

References (13)

1. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 2:104-107, 1996
2. Sunderland MC, Osborne CK: Tamoxifen in premenopausal patients with metastatic breast cancer: A review. J Clin Oncol 9:1283-1297, 1991
3. Stoll BA: Palliation of breast cancer by castration or by hormone administration, in Stoll BA (ed): Breast Cancer Management - Early and Late. London, United Kingdom, Heinemann Medical, 1977, pp 143-146
4. Saphner T, Troxel AB, Tormey DC, et al: Phase II study of goserelin for patients with postmenopausal metastatic breast cancer. J Clin Oncol 11:1529-1535, 1993
5. Bajetta E, Celio L, Zilembo N, et al: Ovarian function suppression with the gonadotrophin-releasing hormone (GnRH) analogue goserelin in premenopausal advanced breast cancer. Tumori 80:28-32, 1994
6. Brambilla C, Escobedo A, Artioli R, et al: Medical castration with Zoladex: A conservative approach to premenopausal breast cancer. Tumori 77:145-150, 1991
7. Bajetta E, Zilembo N, Buzzoni R, et al: Goserelin in premenopausal advanced breast cancer: Clinical and endocrine evaluation of responsive patients. Oncology 51:262-269, 1994
8. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992
9. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15-71-85, 1992
10. Bonnadonna G, Volagussa P, Rossi A, et al: CMF adjuvant chemotherapy in operable breast cancer, in Junes SE, Salmon SE (eds): Adjuvant Therapy of Cancer II. New York, NY, Grune & Stratton, 1979, pp 227-235
11. Ingle JN, Krook JE, Green SJ, et al: Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4:178-185, 1986
12. Buchanan RB, Blarney RW, Durrant KR, et al: A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4:1326-1330, 1986
13. Makuch RW, Johnson MF: Some issues in the design and interpretation of 'negative' clinical studies. Arch Intern Med 146:986-989, 1986